Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 18 04:00PM ET
25.96
Dollar change
-2.17
Percentage change
-7.71
%
IndexRUT P/E- EPS (ttm)-3.91 Insider Own8.65% Shs Outstand26.83M Perf Week-19.78%
Market Cap699.10M Forward P/E- EPS next Y-1.13 Insider Trans-4.20% Shs Float24.60M Perf Month-12.83%
Income-104.16M PEG- EPS next Q-1.50 Inst Own97.30% Short Float16.72% Perf Quarter-23.10%
Sales113.75M P/S6.15 EPS this Y-206.40% Inst Trans-0.13% Short Ratio7.43 Perf Half Y-10.11%
Book/sh9.81 P/B2.65 EPS next Y63.07% ROA-23.41% Short Interest4.11M Perf Year-0.88%
Cash/sh12.75 P/C2.04 EPS next 5Y- ROE-35.12% 52W Range17.52 - 45.00 Perf YTD-17.67%
Dividend Est.- P/FCF66.58 EPS past 5Y12.40% ROI-35.72% 52W High-42.31% Beta2.65
Dividend TTM- Quick Ratio3.26 Sales past 5Y310.16% Gross Margin- 52W Low48.17% ATR (14)2.85
Dividend Ex-Date- Current Ratio3.26 EPS Y/Y TTM-193.29% Oper. Margin-51.90% RSI (14)36.12 Volatility8.89% 8.75%
Employees180 Debt/Eq0.12 Sales Y/Y TTM-59.44% Profit Margin-91.57% Recom1.00 Target Price74.75
Option/ShortYes / Yes LT Debt/Eq0.10 EPS Q/Q-153.37% Payout- Rel Volume1.38 Prev Close28.13
Sales Surprise115.15% EPS Surprise18.94% Sales Q/Q-59.11% EarningsMay 08 AMC Avg Volume553.95K Price25.96
SMA20-25.15% SMA50-15.88% SMA200-12.97% Trades Volume762,495 Change-7.71%
Date Action Analyst Rating Change Price Target Change
Dec-13-23Initiated Canaccord Genuity Buy $90
Jul-24-23Initiated William Blair Outperform $71
May-11-23Upgrade H.C. Wainwright Neutral → Buy $19 → $51
Nov-14-22Resumed Wells Fargo Overweight $35
Nov-10-22Downgrade Robert W. Baird Neutral → Underperform $18
Nov-03-22Upgrade Citigroup Neutral → Buy $22 → $35
Nov-02-22Upgrade Barclays Underweight → Equal Weight $16 → $25
Aug-10-22Downgrade Raymond James Mkt Perform → Underperform
Jul-19-22Resumed Cantor Fitzgerald Overweight $86 → $39
May-11-22Upgrade Robert W. Baird Underperform → Neutral $21 → $18
Jun-15-24 02:49AM
Jun-07-24 10:30AM
Jun-04-24 07:00PM
May-28-24 06:30AM
May-22-24 07:00AM
May-20-24 08:30AM
May-15-24 04:01PM
May-09-24 11:13AM
03:48AM
May-08-24 09:58PM
04:43PM
04:01PM
May-01-24 10:01AM
Apr-25-24 04:01PM
Mar-28-24 01:34AM
Mar-22-24 01:26AM
Mar-09-24 01:09PM
Mar-08-24 12:10PM
06:54AM
Mar-07-24 10:42PM
05:10PM
04:21PM
04:01PM
Mar-04-24 01:23PM
Feb-26-24 03:20PM
09:00AM
Feb-22-24 08:30AM
Feb-21-24 01:04PM
Feb-20-24 04:39PM
09:00AM
Feb-05-24 08:30AM
Jan-23-24 04:16AM
Jan-05-24 01:17PM
Dec-21-23 08:00AM
Dec-17-23 12:03PM
Dec-13-23 10:39PM
Dec-08-23 10:13AM
Dec-04-23 08:30AM
Nov-28-23 08:05AM
07:56AM
Nov-27-23 08:30AM
Nov-15-23 01:26PM
11:30AM
Nov-14-23 05:19PM
04:13PM
04:01PM
10:56AM
Oct-25-23 04:01PM
Oct-23-23 04:01PM
Oct-04-23 11:01PM
08:30AM
Sep-26-23 08:30AM
Sep-19-23 08:30AM
Sep-05-23 08:30AM
Aug-17-23 08:30AM
Aug-14-23 09:00AM
Aug-10-23 07:15AM
Aug-08-23 02:39PM
01:09PM
08:43AM
07:39AM
Aug-07-23 07:50PM
06:43PM
04:01PM
Aug-04-23 09:21AM
Jul-28-23 05:14PM
Jul-24-23 04:01PM
Jul-18-23 06:22AM
Jul-16-23 08:18PM
Jul-14-23 02:36PM
Jul-05-23 06:15AM
Jun-14-23 08:24AM
Jun-01-23 08:30AM
May-18-23 07:16AM
May-12-23 02:04AM
May-09-23 05:35PM
04:37PM
04:01PM
09:29AM
May-08-23 07:43AM
Apr-28-23 01:39PM
Apr-26-23 08:30AM
Apr-17-23 07:10AM
Mar-30-23 08:29AM
Mar-29-23 11:45AM
Mar-28-23 05:15PM
04:01PM
Mar-27-23 09:11AM
Mar-23-23 06:18AM
Mar-07-23 08:00AM
Feb-06-23 08:30AM
Jan-31-23 08:30AM
Dec-28-22 11:35AM
Dec-19-22 08:30AM
Dec-13-22 08:30AM
Dec-12-22 08:30AM
Dec-01-22 10:23AM
Nov-16-22 05:24AM
Nov-12-22 07:04AM
Nov-09-22 05:25PM
Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Markels JohnDirectorJun 14 '24Option Exercise0.003,13103,131Jun 18 09:00 PM
HOLMES EDWARD WDirectorJun 14 '24Option Exercise0.003,13103,131Jun 18 09:01 PM
Marantz Jing L.DirectorJun 14 '24Option Exercise0.003,13103,131Jun 18 09:01 PM
FARRELL PETER CDirectorJun 14 '24Option Exercise0.003,131055,741Jun 18 09:00 PM
BARLOW JAMES FDirectorJun 14 '24Option Exercise0.003,131013,131Jun 18 09:00 PM
Marquet MagdaDirectorJun 14 '24Option Exercise0.003,13103,131Jun 18 09:00 PM
SASSINE ANDYChief Financial OfficerJun 12 '24Sale32.0350,0001,601,500220,526Jun 14 04:06 PM
Chivukula PadChief Scientific Officer & COOJun 05 '24Sale45.001145,130447,334Jun 07 05:01 PM
Chivukula PadChief Scientific Officer & COOJun 03 '24Sale40.0126,0001,040,234447,448Jun 04 04:05 PM
Chivukula PadChief Scientific Officer & COOMar 25 '24Sale35.0217,435610,574473,448Mar 27 04:15 PM
Chivukula PadChief Scientific Officer & COOMar 19 '24Sale35.018,565299,839490,883Mar 21 05:27 PM
Chivukula PadChief Scientific Officer & COONov 01 '23Sale18.725,00093,602499,448Nov 03 04:30 PM
Chivukula PadChief Scientific Officer & COOOct 02 '23Sale25.615,000128,062504,448Oct 04 04:06 PM
Chivukula PadChief Scientific Officer & COOSep 01 '23Sale31.455,000157,264509,448Sep 05 04:05 PM
Chivukula PadChief Scientific Officer & COOAug 01 '23Sale34.915,000174,550514,448Aug 03 04:15 PM
Kummerfeld Keith CSee RemarksJul 14 '23Option Exercise8.966,96862,4087,918Jul 18 06:50 PM
Chivukula PadChief Scientific Officer & COOJul 14 '23Sale35.0125,000875,250519,448Jul 18 06:50 PM
Kummerfeld Keith CSee RemarksJul 14 '23Sale35.006,968243,880950Jul 18 06:50 PM
Chivukula PadChief Scientific Officer & COOJul 03 '23Sale28.755,000143,750544,448Jul 07 06:01 AM